RecruitingNCT07307781

Study of Patient With Frequent Exacerbations in Moscow

Clinical and dEmographic chaRacteristics of Patients With Frequent COPD Exacerbations and Evaluation of Therapeutic Approaches in Treatment in Moscow


Sponsor

AstraZeneca

Enrollment

500 participants

Start Date

Nov 28, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This Study is multicenter, non-interventional, ambispective registry to evaluate the demographic and clinical characteristics, therapeutic approaches and outcomes in COPD outpatients with frequent exacerbations in Moscow


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This observational study in Moscow follows people with moderate to very severe COPD (a serious lung disease) who have frequent flare-ups (called exacerbations), to understand patterns of disease and compare outcomes across different treatment approaches. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of moderate to very severe COPD (confirmed by breathing tests) - You have had at least 2 moderate flare-ups or 1 severe flare-up in the past 12 months - You have been on a stable two-drug inhaled therapy regimen for at least 6 weeks **You may NOT be eligible if...** - You are a current smoker or former smoker with fewer than 10 pack-years - Your COPD has not been confirmed by spirometry (a breathing test) - You are not on the required dual inhaler therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Research Site

Moscow, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07307781


Related Trials